Cargando…

Target Genes of c-MYC and MYCN with Prognostic Power in Neuroblastoma Exhibit Different Expressions during Sympathoadrenal Development

SIMPLE SUMMARY: More than 40% of high-risk neuroblastoma (NB) cases are characterized by aberrations in the transcription factors MYCN and c-MYC. Nevertheless, the developmental stage and mechanisms through which MYCN and c-MYC contribute to the onset and progression of the malignancy are not fully...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yuan, Ye, Alzrigat, Mohammad, Rodriguez-Garcia, Aida, Wang, Xueyao, Bexelius, Tomas Sjöberg, Johnsen, John Inge, Arsenian-Henriksson, Marie, Liaño-Pons, Judit, Bedoya-Reina, Oscar C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527308/ https://www.ncbi.nlm.nih.gov/pubmed/37760568 http://dx.doi.org/10.3390/cancers15184599

Ejemplares similares

The Multiple Faces of MNT and Its Role as a MYC Modulator
por: Liaño-Pons, Judit, et al.
Publicado: (2021)

Expression and activation of nuclear hormone receptors result in neuronal differentiation and favorable prognosis in neuroblastoma
por: Sainero-Alcolado, Lourdes, et al.
Publicado: (2022)

MYCN Function in Neuroblastoma Development
por: Otte, Jörg, et al.
Publicado: (2021)

Targeting of the MYCN Protein with Small Molecule c-MYC Inhibitors
por: Müller, Inga, et al.
Publicado: (2014)

MYCN-amplified neuroblastoma maintains an aggressive and undifferentiated phenotype by deregulation of estrogen and NGF signaling
por: Dzieran, Johanna, et al.
Publicado: (2018)

The MYCN Protein in Health and Disease
por: Ruiz-Pérez, María Victoria, et al.
Publicado: (2017)

Expression of MYCN in Multipotent Sympathoadrenal Progenitors Induces Proliferation and Neural Differentiation, but Is Not Sufficient for Tumorigenesis
por: Mobley, Bret C., et al.
Publicado: (2015)

WNT signaling, the development of the sympathoadrenal–paraganglionic system and neuroblastoma
por: Becker, Jürgen, et al.
Publicado: (2017)

MYCN-enhanced Oxidative and Glycolytic Metabolism Reveals Vulnerabilities for Targeting Neuroblastoma
por: Oliynyk, Ganna, et al.
Publicado: (2019)

Sunitinib Suppress Neuroblastoma Growth through Degradation of MYCN and Inhibition of Angiogenesis
por: Calero, Raul, et al.
Publicado: (2014)

Targeting mitochondrial metabolism for precision medicine in cancer
por: Sainero-Alcolado, Lourdes, et al.
Publicado: (2022)

Lineage-restricted sympathoadrenal progenitors confer neuroblastoma origin and its tumorigenicity
por: Yang, Chia-Lung, et al.
Publicado: (2020)

Inhibitors of ribosome biogenesis repress the growth of MYCN-amplified neuroblastoma
por: Hald, Øyvind H., et al.
Publicado: (2018)

MYCN Amplification Is Associated with Reduced Expression of Genes Encoding γ-Secretase Complex and NOTCH Signaling Components in Neuroblastoma
por: Agarwal, Prasoon, et al.
Publicado: (2023)

MYCN and Metabolic Reprogramming in Neuroblastoma
por: Bansal, Mohit, et al.
Publicado: (2022)

Metastasis in neuroblastoma: the MYCN question
por: Bhavsar, Swapnil Parashram
Publicado: (2023)

Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas
por: Westermann, Frank, et al.
Publicado: (2008)

Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study
por: Wang, L L, et al.
Publicado: (2015)

Interplay between MycN and c-Myc regulates radioresistance and cancer stem cell phenotype in neuroblastoma upon glutamine deprivation
por: Le Grand, Marion, et al.
Publicado: (2020)

Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study
por: Berbegall, Ana P., et al.
Publicado: (2018)

Ferroptosis vulnerability in MYCN‐driven neuroblastomas
por: Dasgupta, Shayani, et al.
Publicado: (2022)

MYCN Amplifications and Metabolic Rewiring in Neuroblastoma
por: Pouliou, Marialena, et al.
Publicado: (2023)

Tumor Development, Growth Characteristics and Spectrum of Genetic Aberrations in the TH-MYCN Mouse Model of Neuroblastoma
por: Rasmuson, Agnes, et al.
Publicado: (2012)

Implementation of the plasma MYCN/NAGK ratio to detect MYCN amplification in patients with neuroblastoma
por: Su, Yan, et al.
Publicado: (2020)

MYCN upregulates the transsulfuration pathway to suppress the ferroptotic vulnerability in MYCN-amplified neuroblastoma
por: Floros, Konstantinos V., et al.
Publicado: (2022)

Immune suppression by myeloid-derived suppressor cells, MDSCs, in MYCN-driven neuroblastoma provides a potential target for cancer immunotherapy
por: Eissler, Nina, et al.
Publicado: (2014)

MycN promotes TRPM7 expression and cell migration in neuroblastoma through a process that involves polyamines
por: Lange, Ingo, et al.
Publicado: (2014)

Metabolic rewiring in MYC-driven medulloblastoma by BET-bromodomain inhibition
por: Graziani, Vittoria, et al.
Publicado: (2023)

MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma
por: Agarwal, Saurabh, et al.
Publicado: (2018)

Therapeutic potential of targeting MYCN: A case series report of neuroblastoma with MYCN amplification
por: Huang, Can, et al.
Publicado: (2020)

A MYCN-independent mechanism mediating secretome reprogramming and metastasis in MYCN-amplified neuroblastoma
por: Zhang, Hai-Feng, et al.
Publicado: (2023)

Regulation of MYCN expression in human neuroblastoma cells
por: Jacobs, Joannes FM, et al.
Publicado: (2009)

MYCN and mutationally activated ALK synergise in neuroblastoma
Publicado: (2012)

MYCN amplification and ATRX mutations are incompatible in neuroblastoma
por: Zeineldin, Maged, et al.
Publicado: (2020)

MYCN in Neuroblastoma: “Old Wine into New Wineskins”
por: Braoudaki, Maria, et al.
Publicado: (2021)

Targeting MYCN and ALK in resistant and relapsing neuroblastoma
por: Tucker, Elizabeth R, et al.
Publicado: (2019)

The MicroRNA Landscape of MYCN-Amplified Neuroblastoma
por: Misiak, Danny, et al.
Publicado: (2021)

PROTAC Bromodomain Inhibitor ARV-825 Displays Anti-Tumor Activity in Neuroblastoma by Repressing Expression of MYCN or c-Myc
por: Li, Zhiheng, et al.
Publicado: (2020)

MYCN is amplified during S phase, and c-myb is involved in controlling MYCN expression and amplification in MYCN-amplified neuroblastoma cell lines
por: Aygun, Nevim, et al.
Publicado: (2019)

Attenuation of sympathoadrenal responses and anesthetic requirement by dexmedetomidine
por: Laha, Arpita, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_nrj0v3u26pp6tjohkscd8kacfe